Antibiotic Use in Sub-Saharan Africa: Challenges and Strategies

By Crystal Lubbe

October 29, 2024

The article titled “Antibiotic prescription sources and use among under-5 children with fever/cough in sub-Saharan Africa” provides a critical analysis of antibiotic use and prescription sources for children under 5 with fever or cough in sub-Saharan Africa (SSA). In particular, this analysis sheds light on the significant issue of antibiotic misuse, thereby emphasising the necessity for appropriate interventions.

Methodology

The study used data from the Demographic and Health Surveys (DHS) from 2006 to 2021, covering 37 SSA countries and including 18,866 children under 5 with fever or cough.

Main Findings

Overall, the majority of children received antibiotics from unqualified sources, which highlights a significant issue with inappropriate use in the region. Moreover, the study identified that children with formally educated mothers were more likely to receive antibiotics from qualified sources. This finding stressed the vital role of maternal education in improving antibiotic prescription sources.

Implications and Recommendations

Consequently, these findings stress the need to address healthcare disparities, enhance access to qualified providers, and promote maternal education, to ensure proper antibiotic use. Moreover, there is an urgency for targeted interventions and policies to optimise antibiotic prescribing practices and combat AMR in sub-Saharan Africa.

Antimicrobial Resistance

The World Health Organization’s 2022 report highlights AMR as a leading cause of death, attributing 5 million deaths in 2019 to bacterial AMR. The United Nations warns that AMR can lead to 10 million deaths annually by 2050, resulting in severe economic consequences.

Gap in Existing Literature

The study addresses a gap by focusing on children under 5 with fever or cough in SSA. This population has often been overlooked in research, which typically focused on adults or limited simulations in a few countries.

Conclusion

The study offers insights into antibiotic prescription patterns and determinants for children under 5 in sub-Saharan Africa. This stresses the need for effective interventions to ensure proper antibiotic use and reduce antimicrobial resistance risks. Addressing these issues is vital for the health of children in the region.

Reference url

Recent Posts

lenacapavir HIV PrEP access
    

Global Health Partnerships Unite to Expand Access to Lenacapavir for HIV Prevention

💉 How can we ensure equitable access to HIV prevention methods like lenacapavir?

A recent initiative from the Global Fund, supported by key global health organizations, aims to provide affordable access to this new HIV pre-exposure prophylaxis medication.

With a goal to reach 2 million individuals over three years, this coordinated effort seeks to drastically cut HIV infections and align with our commitment to ending AIDS by 2030.

Explore the details of this impactful collaboration and how it could transform HIV prevention.

#SyenzaNews #globalhealth #HealthcareInnovation #MarketAccess

antimicrobial resistance africa
     

Africa’s Health Crisis: Antimicrobial Resistance and Mpox Outbreak

🌍 Are we prepared to tackle the hidden pandemic of antimicrobial resistance (AMR) in Africa?

With AMR rapidly becoming a dominant health crisis, it’s critical to understand its impact on our healthcare systems and most vulnerable populations.

The Africa CDC highlights the urgent need for substantial investment and coordinated responses to combat this escalating threat, alongside the ongoing Mpox outbreak.

Discover the pressing challenges and potential solutions in our latest article.

#SyenzaNews #GlobalHealth #HealthcareInnovation #AntimicrobialResistance #PublicHealth

BioSapien cancer drug delivery
    

BioSapien Innovative Cancer Drug Delivery Solutions

🌟 How is innovation in drug delivery shaping the future of cancer treatment? 🌟

Discover how UAE-based BioSapien is transforming the healthcare landscape with the MediChip™ platform, securing $5.5 million in pre-Series A funding to enhance cancer care.

This innovative solution promises to minimise side effects and improve treatment outcomes for patients, fully embracing the potential of biotechnology in the fight against cancer.

Read more about BioSapien’s journey and its impact on global health!

#SyenzaNews #biotechnology #oncology #innovation #HealthTech

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2024 Syenza™. All rights reserved.